M. Iacobelli

发表

Progress in the contemporary management of hemophilia: The new issue of patient aging.

P. Mannucci, M. Iacobelli, 2017, European journal of internal medicine.

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.

R. D'Agostino, A. Krishnan, J. Massaro, 2016, Blood.

Endothelial dysfunction and its critical role in COVID‐19‐associated coagulopathy: Defibrotide as an endothelium‐protective, targeted therapy

P. Richardson, C. Carlo-Stella, M. Iacobelli, 2021, EJHaem.

Differentiation of Human Tumour‐associated Dendritic Cells into Endothelial‐like Cells: An Alternative Pathway of Tumour Angiogenesis

S. Haffner, E. Holler, R. Andreesen, 2007, Scandinavian journal of immunology.

Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias

K. Anderson, P. Richardson, M. Boccadoro, 2009, Clinical Cancer Research.

The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity

P. Richardson, M. Iacobelli, J. Fareed, 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Response to Maccio et al, “Multifactorial pathogenesis of COVID‐19‐related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?”

M. Díaz-Ricart, C. Carlo-Stella, G. Yanik, 2020, Journal of Thrombosis and Haemostasis.

The use of defibrotide in blood and marrow transplantation.

P. Richardson, M. Iacobelli, B. Nejadnik, 2018, Blood advances.

Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.

Allen R. Chen, H. Uno, Lee-Jen Wei, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.

P. Richardson, S. Grupp, Maja Miloslavsky, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Defibrotide for the treatment of hepatic veno‐occlusive disease: results of the European compassionate‐use study

T. Barbui, P. Neumeister, R. Chopra, 2000, British journal of haematology.

Recombinant Factor VIIa–Mediated Activation of Prothrombin Complex Concentrates

M. Iacobelli, D. Hoppensteadt, J. Fareed, 2017, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program.

P. Richardson, M. Mohty, D. Niederwieser, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action.

P. Richardson, C. Stein, L. Benimetskaya, 2006, Oligonucleotides.

Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population.

D. Neuberg, A. Krishnan, P. Richardson, 1998, Blood.

Oligotide, a defibrotide derivative, protects human microvascular endothelial cells against fludarabine-induced activation, damage and allogenicity

S. Blüml, S. Haffner, E. Holler, 2005, Bone Marrow Transplantation.

Defibrotide Interferes With Several Steps of the Coagulation-Inflammation Cycle and Exhibits Therapeutic Potential to Treat Severe Malaria

R. Schwarz, J. Ribeiro, G. Jaramillo-Gutierrez, 2012, Arteriosclerosis, thrombosis, and vascular biology.

Final results from a defibrotide treatment‐IND study for patients with hepatic veno‐occlusive disease/sinusoidal obstruction syndrome

P. Richardson, S. Grupp, R. Soiffer, 2018, British journal of haematology.

Diagnostic Criteria for Hematopoietic Stem Cell Transplantation-Associated Microangiopathy (TAM): Results of a Consensus Process by an International Working Group.

J. Moake, J. George, B. Lämmle, 2005 .

In vivo Skin Penetration, Radical Protection, and Structural Changes after Topical Application of a Herbal Oil Cream Compared to Topical Calcipotriol in Mild to Moderate Psoriasis

J. Lademann, M. Darvin, M. Meinke, 2021, Skin Pharmacology and Physiology.

Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial

A. Schulz, G. Dini, B. Gruhn, 2012, The Lancet.

Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.

Allen R. Chen, A. Krishnan, P. Richardson, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease.

P. Richardson, C. Stein, L. Benimetskaya, 2008, Blood.

Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group.

J. Moake, J. George, B. Lämmle, 2007, Haematologica.

Risk Factors and Severe Outcome in Thrombotic Microangiopathy After Allogeneic Hematopoietic Stem Cell Transplantation

E. Lanino, F. Locatelli, M. Iacobelli, 2006, Transplantation.

COVID‐19‐induced endotheliitis: emerging evidence and possible therapeutic strategies

P. Richardson, R. Soiffer, C. Carlo-Stella, 2021, British journal of haematology.

In Vitro Monitoring of Defibrotide Prophylaxis for Endothelial Complications Following Allogeneic Stem Cell Transplantation.

M. Haubitz, E. Holler, R. Andreesen, 2006 .

Defibrotide: An endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo

G. Koehl, E. Geissler, S. Haffner, 2007, Cancer biology & therapy.

Prolonged Administration of Defibrotide Is Non-Immunogenic in Rats and Dogs.

M. Iacobelli, J. Cunanan, D. Hoppensteadt, 2009 .

Defibrotide Blunts the Prothrombotic Effect of Thalidomide on Endothelial Cells

P. Richardson, M. Iacobelli, J. Fareed, 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

M. Boccadoro, D. Rossi, G. Gaidano, 2010, Haematologica.

Drug Safety Information Through the Internet

G. Trifirò, A. Caputi, L. Sautebin, 2009, Drug safety.

of action in severe hepatic veno-occlusive disease Angiogenesis alteration by defibrotide: implications for its mechanism

P. Richardson, C. Stein, L. Benimetskaya, 2013 .

Use of naltrexone for the treatment of opiate addiction in Campania, Italy: the role of family

M. Iacobelli, F. Mazzeo, G. Falcone, 2003 .

A Meta-Analysis Evaluating the Incidence of Bleeding Events With Intravenous Defibrotide Treatment Outside the Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Setting

M. Iacobelli, S. Aggarwal, O. Topaloglu, 2020, Clinical and applied thrombosis/hemostasis.

Defibrotide (DF) for the Treatment of Severe Veno-Occlusive Disease (VOD) and Multi-System Organ Failure (MOF) Post SCT: Final Results of a Phase II, Multicenter, Randomized Study and Preliminary Analyses of Surrogate Markers and Ultrasound Findings.

Zhezhen Jin, P. Richardson, E. Guinan, 2004 .